Tolerability (toxicity, dose intensity and quality adjusted 648 survival (QAS)) of ECMF versus CMF in the national epirubicin adjuvant trial (NEAT) of moderate risk early breast cancer.
BREAST CANCER RESEARCH AND TREATMENT（2002）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined